Predicting and characterizing selective multiple drug treatments for metabolic diseases and cancer

BMC Systems Biology

Volumn 6, Issue , 2012, Pages

  Facchetti, Giuseppe ^a   Zampieri, Mattia ^b   Altafini, Claudio ^a  

^a SISSA   (Italy)

^b ETH ZURICH   (Switzerland)

Author keywords

Cancer; Drug synergism; Flux balance analysis; Metabolic diseases; Metabolic network

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEOME;

ALGORITHM; ANIMAL; BIOLOGICAL MODEL; COMPUTER ASSISTED DRUG THERAPY; COMPUTER SIMULATION; DRUG DESIGN; DRUG EFFECTS; DRUG INTERACTION; DRUG POTENTIATION; HUMAN; METABOLIC DISEASES; METABOLISM; NEOPLASMS; PROCEDURES; SIGNAL TRANSDUCTION; ARTICLE; DRUG EFFECT; METABOLIC DISORDER; METHODOLOGY; NEOPLASM;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPUTER SIMULATION; DRUG DESIGN; DRUG INTERACTIONS; DRUG SYNERGISM; DRUG THERAPY, COMPUTER-ASSISTED; HUMANS; METABOLIC DISEASES; MODELS, BIOLOGICAL; NEOPLASMS; PROTEOME; SIGNAL TRANSDUCTION;

EID: 84865425410     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-6-115     Document Type: Article

References (59)

1. Lehar J, Krueger A, Zimmermann G, Borisy A. High-order combination effect and biological robustness. Mol Syst Biol 2008, 4:215.. 10.1038/msb.2008.51, 2538911, 18682705.
2. Chou T. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58(3):621-681. 10.1124/pr.58.3.10, 16968952.
3. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005, 26:178-182. 10.1016/j.tips.2005.02.007, 15808341.
4. Yeh P, Tschumi A, Kishony R. Functional classification of drugs by properties of their pairwise interaction. Nature Gen 2006, 38(4):489-494.
5. Keith C, Borisy A, Stockwell B. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005, 4:1-8.
6. Yeh P, Kishony R. Networks from drug-drug surface. Mol Syst Biol 2007, 3:85-87. 1828754, 17332759.
7. Segré D, De Luna A, Church G, Kishony R. Modular epistasis in yeast metabolism. Nat Genet 2005, 37(1):77-83.
8. Suthers P, Zomorrodi A, Maranas C. Genome-scale gene/reaction essentiality and synthetic lethality analysis. Mol Syst Biol 2005, 5:301.
9. Burgard A, Pharkya P, Maranas C. OptKnock: A bilevel programming framework for identifying gene knockout strategies for microbial strain optimization. Biotechnol Bioeng 2003, 84(6):647-657. 10.1002/bit.10803, 14595777.
10. Sridhar P, Song B, Kahveci T, Ranka S. Mining metabolic networks for optimal drug targets. Pac Symp Biocomput 2008, 13:291-302.
11. Kaelin W. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005, 5:689-698. 10.1038/nrc1691, 16110319.
12. Goh K, Cusick M, Valle D, Childs B, Vidal M, Barabási A. The human disease network. Proc Natl Acad Sci USA 2007, 104(21):8685-8690. 10.1073/pnas.0701361104, 1885563, 17502601.
13. Ferrannini E. Physiological and metabolic consequences of obesity. Metabolism 1995, 44(3):15-17.
14. Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, Shlomi T. Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol 2011, 7:501.. 10.1038/msb.2011.35, 3159974, 21694718.
15. Palsson B. Systems Biology: Properties of Reconstructed Networks 2006, New York:Cambridge University Press.
16. Raman K, Chandra N. Flux balance analysis of biological systems: applications and challenges. Brief Bioinform 2009, 10(4):435-449. 10.1093/bib/bbp011, 19287049.
17. Deutscher D, Meilijson I, Kupiec M, Ruppin E. Multiple knockout analysis of genetic robustness in the yeast metabolic network. Nat Gen 2006, 38(9):993-998.
18. Vazquez A. Optimal drug combinations and minimal hitting sets. BMC Syst Biol 2009, 3:81-87. 10.1186/1752-0509-3-81, 2738654, 19660129.
19. Imielinski M, Belta B. Deep epistasis in human metabolism. Chaos 2010, 20(2):026104. 10.1063/1.3456056, 2909311, 20590333.
20. Segré D, Vitkup D, Church G. Analysis of optimality in natural and perturbed metabolic networks. Proc Natl Acad Sci USA 2002, 99(23):15112-15117. 10.1073/pnas.232349399, 137552, 12415116.
21. Shlomi T, Berkman O, Ruppin E. Regulatory on/off minimization of metabolic flux changes after genetic perturbations. Proc Natl Acad Sci USA 2005, 102(21):7695-7700. 10.1073/pnas.0406346102, 1140402, 15897462.
22. Snitkin E, Mackay T, Segrè D Epistatic interaction maps relative to multiple metabolic phenotypes. PLoS Genet 2011, 7(2):e1001294. 10.1371/journal.pgen.1001294, 3037399, 21347328, Segrè D.
23. Salter A. Overview. Trimethoprim-sulfamethoxazole: an assessment of more than 12 years of use. Rev Infect Dis 1982, 4(2):196-236. 10.1093/clinids/4.2.196, 7051224.
24. Weinreb O, Amit T, Bar-Am O, Youdim M. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 2010, 92(3):330-344. 10.1016/j.pneurobio.2010.06.008, 20600573.
25. Duarte N, Becker S, Jamshidi N, Thiele I, et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. PNAS 2007, 104(6):1777-1782. 10.1073/pnas.0610772104, 1794290, 17267599.
26. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2011, 39(Suppl 1):D1035-D1041. 3013709, 21059682.
27. Mansour M, Schwarts D, Judd R, Akingbemi B, Braden T, Morrison E, Dennis J, Bartol F, Hazi A, Napier I, Abdel-Mageed A. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer. Int J Oncol 2010, 38(2):537-546.. 103892/ijo2010877, 21170507.
28. Luberto C, Hannun Y. Ceramide in the eukaryotic stress response. Trends Cell Biol 2000, 10(2):73-80. 10.1016/S0962-8924(99)01694-3, 10652518.
29. Obeid L, Hannun Y. The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 2002, 277:25847-25850. 10.1074/jbc.R200008200, 12011103.
30. Yang G, Badeanlou L, Bielawski J, Roberts A, Hannun Y, Samad F. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab 2009, 297:E211-E224. [http://ajpendo.physiology.org/content/297/1/E211.abstract], 2711669, 19435851.
31. Triola G, Fabrias G, Dragusin M, Niederhausen L, Broere R, et al. Specificity of the Dihydroceramide Desaturase Inhibitor N-[(1R,2S)-2-Hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]o ctanamide (GT11) in Primary Cultured Cerebellar Neurons. Mol Pharmacol 2004, 66(6):1671-1678. 10.1124/mol.104.003681, 15371559.
32. Munoz-Olaya J, Matabosch X, Bedia C, Egido-Gabs M, Casas J, et al. Synthesis and biological activity of a novel inhibitor of Dihydroceramide Desaturase. Chem Med Chem 2009, 3:946-953.
33. Llaverias G, Lacasa D, Viñals M, Vázquez-Carrera M, Sánchez R, Laguna J, Alegret M. Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin. Biochem pharmacol 2004, 68:155-163. 10.1016/j.bcp.2004.03.009, 15183127.
34. Freed M, Ratner R, Marcovina S, Kreider M, Biswas N, Cohen B, Brunzell J. Effects of Rosiglitazone alone and in combination with Atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Ame J Cardiology 2002, 90(9):947-952.
35. De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda C, Tognoni G, Valentini U, Nicolucci A, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007, 8:21. 10.1186/1745-6215-8-21, 2014771, 17725825.
36. Armstrong P, Lorell B, Nissen S, Borer J. 97th Meeting of the Cardiovascular and Renal Drugs Advisory Committee July 18th and 19th, 2002. Circulation 2002, 106(6):e9011-e9012.
37. Murtola T, Pennanen P, Syvälä H, Bläuer M, Ylikomi T, Tammela T. Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations. Prostate 2009, 69(9):1017-1023. 10.1002/pros.20951, 19301305.
38. Weiss G, Garnick M, Osteen R, Steele G, Wilson R, Schade D, Kaplan W, Boxt L, Kandarpa K, Mayer R. Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J Clin Oncology 1983, 1(5):337-344.
39. Carter S, Franklin T, Jones D, Leonard B, Mills S, Turner R, Turner W. Mycophenolic acid: an anti-cancer compound with unusual properties. Nature 1969, 223:848-850. 10.1038/223848a0, 5799033.
40. Bleich H, Boro E, Frei III E, Jaffe N, Tattersall M, Pitman S, Parker L. New approaches to cancer chemotherapy with methotrexate. New England J Med 1975, 292(16):846-851.
41. Hazarika M, White R, Johnson J, Pazdur R. FDA drug approval summaries: Pemetrexed (Alimta®). The oncologist 2004, 9(5):482-488. 10.1634/theoncologist.9-5-482, 15477632.
42. Borden K, Culjkovic-Kraljacic B. Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?. Leukemia Lymphoma 2010, 51(10):1805. 10.3109/10428194.2010.496506, 2950216, 20629523.
43. Lam S, McWilliams A, MacAulay C, Wattenberg L, Szabo E, et al. A phase I study of myo-inositol for lung cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 2006, 15(8):1526-1531. 10.1158/1055-9965.EPI-06-0128, 16896044.
44. Cho S, Kim J, Kim J, Lee J, Jung H, Song I. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer 2008, 123(4):951-957. 10.1002/ijc.23593, 18521906.
45. Baumann P, Mandl-Weber S, Völkl A, Adam C, Bumeder I, Oduncu F, Schmidmaier R. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol cancer ther 2009, 8(2):366. 10.1158/1535-7163.MCT-08-0664, 19174558.
46. Zhang G, Tu C, Zhang G, Zhou G, Zheng W. Indomethacin induces apoptosis and inhibits proliferation in chronic myeloid leukemia cells. Leukemia res 2000, 24(5):385-392.
47. Schrell U, Rittig M, Anders M, Kiesewetter F, Marschalek R, Koch U, Fahlbusch R. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg 1997, 86(5):845-852. 10.3171/jns.1997.86.5.0845, 9126901.
48. Antman K. Introduction: the history of arsenic trioxide in cancer therapy. The oncologist 2001, 6(Suppl 2):1-2.
49. von der Maase H, Hansen S, Roberts J, Dogliotti L, Oliver T, Moore M, Bodrogi I, Albers P, Knuth A, Lippert C, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncology 2000, 18(17):3068-3077.
50. Temple Jr C, Bennett Jr L, Rose J, Elliott R, Montgomery J. Synthesis of pseudocofactor analogs as potential inhibitors of the folate enzymes. J Med Chem 1982, 25(2):161-166. 10.1021/jm00344a014, 7057422.
51. Mahfouz M, Johnson S, Holman R. Inhibition of desaturation of palmitic, linoleic and eicosa-8, 11, 14-trienoic acids in vitro by isomeric cis-octadecenoic acids. Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism 1981, 663:58-68.
52. Borges T, Glauert H, Robertson L. Perfluorodecanoic acid noncompetitively inhibits the peroxisomal enzymes enoyl-CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase. Toxicol Appl Pharmacol 1993, 118:8-15. 10.1006/taap.1993.1003, 8430427.
53. Tserng K, Jin S, Hoppel C. Spiropentaneacetic acid as a specific inhibitor of medium-chain acyl-CoA dehydrogenase. Biochemistry 1991, 30(44):10755-10760. 10.1021/bi00108a021, 1931995.
54. Mazumdar V, Snitkin E, Amar S, Segré D. Metabolic network model of a human oral pathogen. J Bacteriol 2009, 191(1):74-90. 10.1128/JB.01123-08, 2612419, 18931137.
55. Hooper L, Gordon J. Commensal host-bacterial relationships in the gut. Science 2001, 292:1115-1118. 10.1126/science.1058709, 11352068.
56. Palsson B, Varma A. Metabolic capabilities of Escherichia coli II: optimal growth pattern. J Theor Biol 1993, 165:503-522.
57. Dempe S. Foundations of bilevel programming 2010, New York: KluwerAcademic Publisher.
58. Matoušek J Gärtner B Understanding and Using Linear Programming 2000, Berlin: Springer, Matoušek J Gärtner B.
59. Schrijver A. Theory of Linear and Integer Programming 1986, New York: JohnWiley Sons.